Adlai Nortye Group Ltd. (ANL) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Adlai Nortye Group Ltd. (ANL) advanced +0.78% to $10.28, trading at 57% of its 52-week range ($0.88 – $17.25). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class AN4035 AN4035 is a nove
Adlai Nortye Group Ltd. (NASDAQ:ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that an oral
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ANL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ANL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Adlai Nortye Group Ltd. (ANL) ranks #320 by composite RQD confidence (52/100, grade D+) and #405 by equity capitalization ($662.0M). Within this direct 5-issuer industry benchmark cohort, ANL leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANL
ACTIVE
Adlai Nortye Group Ltd. | D+ | 52/100 | — | — | — | +0.78% | $662.0M | Benchmark Subject |
| IMMX Immix Biopharma Inc. | E | 33/100 | — | — | -35.0% | -1.78% | $661.6M | /immx-vs-anl → |
| LXRX Lexicon Pharmaceuticals Inc. | D- | 39/100 | — | 96.0% | -31.5% | -0.34% | $658.5M | /lxrx-vs-anl → |
| ABUS Arbutus Biopharma Corporation | E | 22/100 | — | — | -35.0% | -0.93% | $656.0M | /abus-vs-anl → |
| BCAX Bicara Therapeutics Inc. | D | 45/100 | — | — | -35.0% | -0.31% | $643.9M | /bcax-vs-anl → |
Adlai Nortye Group Ltd. (ANL) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $662.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Adlai Nortye Group Ltd. (NASDAQ: ANL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $10.28 (+0.78% 1D, market cap $662.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ANL ranks #320 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANL carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IMMX (Immix Biopharma Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M) and LXRX (Lexicon Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -31.5%, cap $658.5M). Among the 5-stock peer group, ANL leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
For Adlai Nortye Group Ltd. (ANL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #320 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
ANL last traded at $10.28 (+0.78% on volume of 44,562 shares), positioning the stock -25.62% below its 50-day simple moving average ($13.82) and -9.75% below its 200-day simple moving average ($11.39). Across its 52-week range of $0.88 to $17.25, ANL sits at the 57.4% percentile with a 14-day RSI of 31.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($9.00 to $11.56).
Why ANL Stock advanced +0.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.